Pharma Focus Asia

Finch Therapeutics & Takeda Expand Collaboration to Develop Microbiome Therapeutics Using Finch’s Human-First Discovery® Platform

Thursday, November 14, 2019

Finch Therapeutics Group, Inc. (“Finch”) and Takeda Pharmaceutical Company Limited announced today the expansion of their collaboration to develop microbiome-based therapeutics using Finch’s Human-First Discovery® platform. Under the terms of the expanded agreement, Finch and Takeda will utilize Finch’s platform to target Crohn’s disease, a form of inflammatory bowel disease.

Finch’s Human-First Discovery platform enables the development of Full-Spectrum Microbiota® (FSM®) therapies that contain a diverse community of microbiota from human donors, as well as Rationally-Selected Microbiota® (RSM®) therapies that contain select bacterial strains, grown in pure culture, that have been linked to favorable clinical outcomes in human microbiota transplantation studies. In collaboration with Takeda, Finch’s first RSM product, FIN-524, is advancing through pre-clinical development for the treatment of ulcerative colitis.

“We are pleased to expand our collaboration with Takeda,” said Mark Smith, PhD, CEO of Finch. “We’ve had a very fruitful collaboration with Takeda on the development of FIN-524, and we look forward to utilizing the knowledge we’ve built together to pursue the development of new therapeutic options for an even wider group of patients battling IBD.”

“We’ve seen the promise of Finch’s Human-First Discovery platform for the development of a completely new type of treatment for inflammatory bowel disease,” said Gareth Hicks, PhD, Vice President & Head of Gastroenterology Drug Discovery Unit at Takeda. “Through our work with Finch to understand the therapeutic potential of the microbiome, we hope to develop new treatment options that make a meaningful difference for individuals living with IBD.”

Under the terms of the agreement, Takeda will receive exclusive worldwide rights to commercialize an RSM product developed for Crohn’s disease. Financial terms of the agreement were not disclosed.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024